In 2014, researchers condemned the Spanish Government for “destroying the R&D horizon of Spain and the future of a complete generation” in the acknowledgment section of a paper about wireless networks.
Jens Förster, a high-profile social psychologist, has agreed to retract multiple papers following an institutional investigation — but has also fought to keep some papers intact. Recently, one publisher agreed with his appeal, and announced it would not retract two of his papers, despite the recommendation of his former employer.
Last month, the American Psychological Association (APA) announced it would not retract two papers co-authored by Förster, which the University of Amsterdam had recommended for retraction in May, 2015. The APA had followed the university’s advice last year and retracted two other papers, which Förster had agreed to as part of a settlement with the German Society for Psychology (DGPs). But after multiple appeals by Förster and his co-authors, the publisher has decided to retain the papers as part of the scientific record.
Many voices contributed to the discussion about these two papers — in November, 2016, the University of Amsterdam announced it was rejecting the appeal by another co-author on both papers, Nira Liberman, based at Tel Aviv University in Israel. The following month, Tel Aviv University announced that it believed the articles should not be retracted, based on its own internal review.
The APA reviewed the various recommendations, according to last month’s announcement:
A journal has retracted a 2012 paper after determining that the authors had already published it elsewhere.
According to the retraction notice, the editors-in-chief of the Journal of Occupational Medicine and Toxicology concluded that the article had been published in another journal—In Vitro Cellular & Developmental Biology – Animal—the previous month. The authors, however, did not agree to the retraction.
The research, led by Ali Khavanin, who is based at Tarbiat Modares University in Tehran, Iran and is corresponding author on both papers, evaluated whether the vibrations from industrial machinery can harm hearing in rabbits (1,2).
Against the authors’ objections, Nature Methods has added an expression of concern to a 2017 paper that drew fire for suggesting a common gene editing technique could cause widespread collateral damage to the genome. The latest note — the second to be added in two months — alerts readers to an alternative interpretation of the findings.
When “Unexpected mutations after CRISPR–Cas9 editing in vivo” was published May 30, it immediately drew criticism from many of the top scientists working with CRISPR, including those associated with companies seeking to develop CRISPR-based therapies for humans. Share prices for the two largest companies pursuing CRISPR therapies, Editas Medicine and Intellia Therapeutics, dropped following publication of the article.
In the fall of 2015, out-of-work stem cell biologist Mavi Camarasa decided she had waited long enough. It had been three years since she and a colleague were, best they could tell, the first to successfully correct the most common cystic fibrosis mutation in stem cells derived from a patient.
But her former lab director, Daniel Bachiller, had blocked her from writing even a short report, she told Retraction Watch:
He said we are not submitting at this time, wait until [the project is] complete. “Wait, wait,” is the only answer I’d had from him ever.
Though she’d left the Spanish regenerative medicine lab in 2013 to take care of an ailing parent and had mostly been scooped by another group in April of that year, Camarasa thought she still might be able to get something out of the project. She hatched a plan to make him an offer he couldn’t refuse — an already accepted manuscript where all he would have to do is attach his name at the last minute.
But this story didn’t turn out exactly how she’d hoped — and illustrates how the pressure to publish can affect researchers at different levels in the lab.
The corresponding author of a 2015 nanotechnology paper has penned a lengthy — and revealing — retraction notice, explaining why he is not certain about the findings.
In the notice, Chang Ming Li from the Institute for Clean Energy & Advanced Materials (ICEAM) at Southwest University in China, states that there is “insufficient evidence to conclusively” identify the composition of the nanowire array described in the article, which “severely undermines the validity of the reported conclusions.”
The 2015 paper has been considered “highly cited” by Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters, meaning it has received a disproportionate amount of cites given its field and publication year.
Li also said that the paper — which appeared in Physical Chemistry, Chemical Physics — was “submitted and published without my knowledge or permission.” He has not responded to our request to explain how that could have happened, given that he was the corresponding author. Continue reading Author retracts nanotechnology paper over doubts about key results
The first author of a 2013 chemistry paper is objecting to his co-authors’ decision to retract the paper, which contains duplicated figures.
We recently encountered a similar scenario with papers by first author Khalid Mahmood. In late 2015, Mahmood lost three papers in the journal ACS Applied Materials & Interfaces over duplicated images. One of the notices also indicated that the figures had “been published elsewhere and identified with different samples” — the same language used in the notice of the most recent retraction, in Journal of Materials Chemistry C.
Mahmood performed the work on the papers at Korea Advanced Institute of Science and Technology (KAIST), along with his two co-authors, Seung Bin Park and Hyung Jin Sung (also co-authors on two of the retracted papers in ACS Applied Materials & Interfaces).
A physics journal has retracted a 2011 paper by a group of scientists based in Italy, noting it’s “literally copied” from a paper by the same authors.
This is the 12th retraction for the paper’s first author Alberto Carpinteri, who is known in the engineering community for championing some controversial ideas, such as that the Shroud of Turin is as old as Jesus (contradicting carbon dating). In 2015, a journal he used to edit — Meccanica — retracted 11 of his papers, noting that “the editorial process had been compromised.”
In the latest notice, the Journal of Statistical Mechanics: Theory and Experiment (JSTAT) says its investigation found a substantial portion of the paper—including the main analysis and conclusion—had been lifted from a paper published in another journal several months before.
A journal has temporarily removed a paper showing the dramatic differences in the cost of providing emergency care that caught national attention (and some criticism from emergency care providers), despite the first author’s claims that the results are valid.
The paper, published online in February by the Annals of Emergency Medicine, showed that it can cost significantly more for patients to be treated at emergency departments than at urgent care centers, even for the same conditions. Soon after the paper was published, first author Vivian Ho at Rice University was told by the American College of Emergency Physicians, which publishes the journal, that there were some errors in the appendix, and they wanted to reanalyze the entire paper.
PLOS ONE has issued an expression of concern after the authors of a controversial study about chronic fatigue syndrome declined to share some of their data.
In an unusual move, the journal included the authors’ response to the expression of concern (EOC), in which they strongly argue against the notice, and “do not accept that it is justified.”
There have been numerous requests for data from the “PACE” trial, as the clinical trial is known. Patients and advocates have long disputed the results, arguing that suggesting cognitive behavior and graded exercise therapy could cause harm.
In the latest notice, the journal says it consulted two editorial board members about the paper, a 2012 sub analysis of a controversial clinical trial on chronic fatigue syndrome. The journal then asked the authors to provide the data behind five tables, which would enable researchers to replicate the cost-effectiveness analyses the authors report for different therapies — including graded exercise therapy, which some patient advocates believe could be harmful.
As with previous requests for data, the authors refused to provide it, citing patient confidentiality and consent. The notice explains: